IL33 and diabetes mellitus: TG mice treated with IL-33 (12–18 days of experiment) were more resistant to MLD–STZ–induced diabetes as evaluated by all metabolic parameters (Figure 6 panel A, B, C, D), particularly in the glucose tolerance test (Figure 6 panel E), compared to the TG mice without IL-33 treatment.